Eric Schuur: Dr. Schuur serves as Hepatx President and Chief Executive Officer.  He has over 25 years of experience as a scientist, manager, and consultant.  He has deep scientific expertise from the bench level to the clinic at places such as UCLA, Stanford, and the Scripps Research Institute. Dr. Schuur has extensive industry experience with early stage companies, including Calydon, Inc. and Asthmatx, Inc. where he has managed preclinical and clinical research teams.  As a consultant, he provided medical and scientific strategy, communications, and information management services for companies in the the regenerative medicine, gene therapy, genomics, diagnostics, and biomarkers fields.  Dr. Schuur has a PhD in Experimental Pathology from the UCLA School of Medicine and completed an NIH-sponsored post-doctoral fellowship at the Scripps Research Institute.  Dr. Schuur serves as an Adviser to the Stanford School of Medicine SPARK Program and as a Mentor in the Stanford University Office of Technology Licensing Innovation Farm Team Program.

Mark Chao.jpg

Mark Chao: Dr. Chao serves as Hepatx Vice President of Clinical Development.  He is a board-certified physician in internal medicine and a trained hematologistwith a strong clinical network at Stanford University Hospitals. Dr. Chao has clinical development experience in bringing cancer therapeutics through to successful IND filing and has contributed to successful phase I clinical trial execution within the academic university setting.  Dr. Chao’s has over 10 years of experience in stem cell biology, immunology, and cancer biology research, including the discovery of a novel target for cancer immunotherapy that is now in clinical development.  He earned his MD and PhD in cancer biology from Stanford University and is affiliated with Stanford as a hematology fellow.